TITLE

AGENNIX AG GETS POSITIVE RESULTS FROM TALACTOFERRIN TRIAL

PUB. DATE
January 2010
SOURCE
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
47191578

 

Related Articles

  • Agennix Finishes Recruitment for NSCLC Drug's Phase III. Moran, Nuala // BioWorld International;3/23/2011, Vol. 16 Issue 12, p1 

    The article reports that AgenniX AG has completed recruitment for the Phase III trial of talactoferrin, a drug being developed for non-small-cell lung cancer (NSCLC). The Munich, Germany-based company is also preparing a Phase IIb trial of the drug for sepsis. Chief medical officer Rajesh Malik...

  • Agennix Nosedives on Surprise Ph III Lung Cancer Drug Failure. Moran, Nuala // BioWorld Today;8/8/2012, Vol. 23 Issue 153, p1 

    The article reports on the failed results of Agennix AG's Phase III trial for its talactoferrin for lung cancer treatment. It notes that talactoferrin, the immune modulator, failed to improve overall survival when administered in addition to best supportive care in the placebo-controlled trial...

  • drug approval.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p694 

    A definition of the term "drug approval," which refers to the formal process through which drugs are tested before they are allowed for selling, is presented.

  • Agennix's Phase II/III Study Halted by Mortality Finding. Moran, Nuala // BioWorld International;2/8/2012, Vol. 17 Issue 6, p1 

    This article reports that the Phase II/III clinical trial of Agennix AG's talactoferrin drug after a review of the data safety monitoring board (DSMB) found 28-day mortality in patients receiving the drug, which was greater than in the placebo. Agennix AG is disappointed and surprised by the...

  • Agennix Preps for Public Offering, Bolsters Bottom Line. Moran, Nuala // BioWorld International;7/28/2010, Vol. 15 Issue 30, p1 

    The article focuses on a loan secured by Agennix AG to prepare for a public offering in late 2010. The loan, which amounted to 15 million euros will be used by the company to boost its financial status prior to a public offering aimed to raise up to 60 million euros. According to Torsten...

  • Agennix Restructures, Cuts Staff In Wake of Talactoferrin Bomb. Sheridan, Cormac // BioWorld Today;8/27/2012, Vol. 23 Issue 166, p2 

    The article reports on the corporate restructuring of Agennix AG. The company has decided to reduce its staff and shut down a small drug development facility in Houston, Texas. The move came after the failure of its lead drug talactoferrin in a Phase III trial in non-small-cell lung carcinoma...

  • Agennix Nets $105M in Share Offer to Develop Talactoferrin. Sheridan, Cormac // BioWorld Today;10/4/2010, Vol. 21 Issue 191, p1 

    The article reports on 78.4 million Euros generated by Agennix AG from a combined rights offering and private placement. Such placement is said to allow the company to continue developing its lead drug candidate, talactoferrin, which is being tested for cancer and sepsis. According to Friedrich...

  • Agennix Nets $105M in Share Offer to Develop Talactoferrin. Sheridan, Cormac // BioWorld International;10/6/2010, Vol. 15 Issue 39, p1 

    The article reports on the 78.4 million euro earned by Agennix AG of Planegg, Germany in a rights offering and private placement deal. The fund will help the company finance the development of its drug talactoferrin for the treatment of cancer and sepsis. Statements from its chief executive...

  • Agennix's Phase II/III Study Halted by Mortality Finding. Moran, Nuala // BioWorld Today;2/8/2012, Vol. 23 Issue 17, p1 

    The article reports that the Phase II/III trial of Agennix AG's talactoferrin has been stopped following a review by the data safety monitoring board (DSMB) which found 28-day mortality in the patients receiving the drug was greater than in the placebo arm. The move has caused Agennix's shares...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics